Compare Star Bulk Carriers Corp (SBLK) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Star Bulk Carriers Corp vs Tango Therapeutics Inc. — how do they compare? Star Bulk Carriers Corp trades at $28.76 (market cap $3.46B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Star Bulk Carriers Corp and Tango Therapeutics Inc. are close in size by market cap, and Star Bulk Carriers Corp pays a 6.31% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Star Bulk Carriers Corp for 23 Days and Tango Therapeutics Inc. for 0 Days on average.
| SBLK | TNGX | |
|---|---|---|
Market Cap | $3.46B | $3.75B |
Volume | 1,078,337 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $32.49 | $32.90 |
52-Week Low | $17.42 | $7.50 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $4.14B | $2.77B |
Dividend Yield | 6.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $29.79, down 0.17% with a bearish technical signal despite strong fundamentals. The company demonstrates robust profitability with 23.87% net income margin and has beaten earnings estimates for three consecutive quarters. Recent insider buying activity and a 58.34% analyst buy rating signal confidence, while the stock offers an attractive valuation with P/E of 11.68 and upcoming $0.90 dividend payment.
SBLK presents a compelling value opportunity with strong earnings momentum and shareholder returns, though technical weakness and shipping sector volatility pose near-term risks. The company's 100% free cash flow distribution policy and projected revenue growth to $1.2B in 2026 support the bullish fundamental case, while bearish moving averages suggest potential consolidation before further upside.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
